Blue Light Fluorescent Cystoscopy


Bladder cancer is the fifth most commonly diagnosed cancer in the US with an estimated 81,0000 new cases each year. Most of these cancers are found at an early stage, however, finding some early stage tumors and lesions may be challenging due to the inconsistent ability to distinguish them from healthy tissue when viewed through a scope only using white light, making these tumors more difficult to treat.

Today, patients have an additional option when undergoing a biopsy or surgical removal (called a resection) of a suspected or known bladder cancer. Urologic Oncology surgeons at UVA are now using Blue Light Cystoscopy with Cysview® (BLCC) to better diagnose, evaluate, and remove bladder cancer tumors and lesions. Clinical trials have shown this procedure to be so effective that it is included in the bladder cancer guidelines published by the American Urological Association (AUA) and the Society of Urological Oncology (SUO).

University of Virginia Urology Department--Bladder image using white-light cystoscopy alone

Bladder image using white-light cystoscopy alone

University of Virginia Urology Department--using blue light Cystoscopy with Cysview as an adjunct to white light.

Same image using blue light Cystoscopy with Cysview as an adjunct to white light

Frequently Asked Questions

UVA Urology was the first facility in the state of Virginia to offer this procedure.

Patients seeking treatment for bladder cancer have many different choices on when it comes to where to go for their care. There are more diagnostic tools and treatments now than ever before. Blue Light Cystoscopy with Cysview is an important tool that can aid in the diagnosis and treatment of bladder cancer, and finding a center that offers this option can make a big difference. Below are the answers to some common questions about Blue Light Cystoscopy with Cysview, and bladder cancer detection and treatment.